A venture capital firm founded in 2017 and is based in Cambridge, MA. The firm focuses on biotech investments with particular interest in the following indications: oncology, immunology, CNS/neurology, among others. The firm also invests in rare and orphan diseases. The firm is generally stage agnostic, and can invest in anywhere from pre-clinical to pre-launch, commercial stage companies. The firm is capable of investing up to $15M over the life of the company, and is open to acting as either the lead/co-lead or co-investor.

The firm focuses on investments in therapeutics companies across all stages of development, from pre-clinical, clinical, to commercial stage. The firm is most interested in indications of high unmet medical need, including oncology, immunology, neurology, and rare diseases and may seek assets in other indications on a case-by-case basis.

The firm seeks to work with companies backed by an experienced management team with strong scientific expertise. The firm invests in both public and private companies, and is open to acting as either the lead/co-lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A life sciences-focused, impact venture capital firm was founded in 2018 and headquartered in New York with offices in Zurich. The firm aims to achieve meaningful social impact in both developed and emerging markets in addition to financial returns. The firm participates in Series A onward rounds, acting as a lead or co-investor, but can engage with companies earlier depending on the nature of the technology and target indications. Initial check sizes range from USD $3-12M with additional capital generally reserved for follow-ons. The firm is open to global companies.

The firm finances promising life science technologies for high-burden public health challenges and threats. This includes, but is not limited to, infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, and other related global health indications. In terms of technologies, the firm has a broad mandate and invests in vaccines, therapeutics, medical devices, diagnostics, and related enabling technologies. The firm generally likes to see opportunities that have demonstrated safety and generated efficacy signals from clinical trials or similar evaluations and compelling proof-of-concept data.

The firm generally prefers to take a board observer seat at minimum. The firm likes to be an active investor such as being involved in corporate strategy and company building.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A single family office based in the US actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries. 
 
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more. 
 
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2021 and located in Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. The firm invests in European companies. 
 
The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies. 
 
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global pharmaceutical firm specialized in the dermatology sector engages in partnerships with early stage companies; these relationships may take a variety of forms, but in most cases the firm forms a partnership around an asset and does not act as a minority equity investor. The firm partners with dermatology startups all around the globe. 
 
The firm is interested in therapeutic programs in the dermatology space, including in acne, dermatology-oncology, and rare diseases of the skin.  The firm will consider partnerships at any stage of development but will only make early stage partnerships if the asset’s risk profile is reasonable. 
 
There are no specific requirements for company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture arm of a hospital system started investing in early-stage companies through their venture team that was founded in 2022. The team focuses primarily in digital health companies seeking Pre-Seed to Series A investment rounds. The team’s mandate is solving clinical or operational challenges through strategic partnerships that align directly with the hospital system’s core values. The firm does not lead capital investments but will integrate strategic partners into the hospital system through pilot programs before eventually investing in equity. The firm’s equity investments are typically between USD $500k – $2M, but the fund can invest more. The fund is looking to invest in 4-6 companies yearly. 
 
The firm invests primarily within digital health companies that are ready to be integrated within the hospital system; the fund is opportunistic to indication and platform within their digital health investments. The firm may also make investments into diagnostics or medical device companies. For medical device investments, the fund prefers to invest in companies that are nearing clinical completion, or already on market. The fund does not invest in therapeutics. 
 
The fund does not have any strict company or management team requirements. Although an experienced management team is preferred, the fund is willing to invest in any company that is willing to provide tag-along rights. The fund invests within North America, Europe, Australia, and South America and is open to global opportunities that are capable of being integrated into the hospital system. The fund does not typically lead investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.